Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;43(10):1945-1954.
doi: 10.1007/s10529-021-03173-3. Epub 2021 Aug 26.

The application of oncolytic viruses in cancer therapy

Yang Gao  1 , Yan Wu  1 , Tian Huan  1 , Xiaoyan Wang  2 , Jun Xu  3 , Qinggang Xu  1 , Feng Yu  4 , Haifeng Shi  5
Affiliations
Review

The application of oncolytic viruses in cancer therapy

Yang Gao et al. Biotechnol Lett. 2021 Oct.

Abstract

Oncolytic therapy is a treatment method used to directly combat tumor cells by modifying the genes of naturally occurring low pathogenic viruses to form "rhizobia" virus. By taking the advantage of abnormal signal pathways in cancer cells, it selectively replicates in tumor cells leading to tumor cell lysis and death. At present, clinical studies widely employ biomolecular technology to transform oncolytic viruses to exert stronger oncolytic effects and reduce their adverse reactions. This review summarizes the current progresses and the molecular mechanism of oncolytic viruses towards tumor treatment and management.

Keywords: Cancer therapy; Immune response; Molecular mechanism; Oncolytic virus.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Bell JC, McFadden G (2015) Editorial overview: oncolytic viruses-replicating virus therapeutics for the treatment of cancer. Curr Opin Virol 13:viii–ix - PubMed - DOI
    1. Bommareddy PK, Shettigar M, Kaufman HL (2018) Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol 18(8):498–513 - PubMed - DOI
    1. Boutros C, Tarhini A, Routier E et al (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13(8):473–486 - PubMed - DOI
    1. Card PB, Hogg RT, Gil Del Alcazar CR, Gerard RD (2012) MicroRNA silencing improves the tumor specificity of adenoviral transgene expression. Cancer Gene Ther 19(7):451–459 - PubMed - PMC - DOI
    1. Chaurasiya S, Fong Y, Warner SG (2020) Optimizing oncolytic viral design to enhance antitumor efficacy: progress and challenges. Cancers (Basel) 12(6):1699 - DOI

LinkOut - more resources